CTOR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Citius Oncology Inc (CTOR) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, financial performance shows declining net income and EPS, and there are no strong positive trading signals or significant catalysts to suggest immediate upside potential. Holding off on investment until clearer positive signals emerge is advisable.
The technical indicators are bearish. The MACD is negative and expanding downward, RSI is neutral at 37.475, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 1.031, with resistance at 1.191. The stock has a 70% chance to decline -2.33% in the next day.
The company reported an 86% overall response rate in a Phase 1 trial of LYMPHIR for high-risk relapsed DLBCL, with a favorable safety profile and potential to enhance CAR-T therapy. Plans for larger studies could indicate future growth potential.
The stock's technical indicators are bearish, and financial performance shows a decline in net income (-16.90% YoY) and EPS (-33.33% YoY). Additionally, hedge funds and insiders are neutral, with no significant trading trends.
In 2026/Q1, revenue remained flat at 3944111 (0.00% YoY). Net income dropped to -5534069 (-16.90% YoY), and EPS fell to -0.06 (-33.33% YoY). Gross margin remained steady at 79.99%. Overall, financial performance indicates declining profitability.
No analyst rating or price target changes provided.
